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Purpose: To study lysyl oxidase-like 1 (LOXL1) expression in freshly collected lens capsules from pseudoexfoliation
syndrome (XFS), pseudoexfoliation glaucoma (XFG), and normal cataract control individuals. We also investigated the
effects of four glaucoma drug medications on LOXL1 expression in primary human lens epithelial cell cultures to see if
they could affect LOXL1 expression.
Methods: Lens capsules were collected at the time of cataract surgery. Controls were matched to age, sex, and ethnicity.
Total RNA was isolated from individual lens capsule samples and real-time PCR was performed on each sample using
primers flanking the sixth exon of the LOXL1 gene. Cell cultures were grown to confluence in four separate six-well plates
at 37 °C in 5% CO2. Each plate was then treated with one of four different glaucoma drugs (brinzolamide 1%, brimonidine
tartrate 0.1%,  timolol  maleate  0.5%,  and  latanoprost  0.005%)  once  daily  for seven days  (at both 1:1,000 and 1:100
concentrations relative to media).  Controls were not  treated with  any drug but media  was changed in the same manner.
After  one  week  of  treatment,  cells were  harvested and  total RNA isolated.  Real-time PCR  was performed on each
group of cells.
Results: Seven XFS, seven XFG, and ten cataract control specimens were analyzed. LOXL1 expression was detected in
the lens capsule specimens from each of the four groups. Significant expression differences were found between the control
and XFG groups and XFS and XFG groups. No significant difference was observed between the control and XFS group.
No significant decrease in LOXL1 expression was seen with drug incubation of the four medications (Brinzolamide,
Timolol, Latanoprost, and Brimonidine) at the 1:1,000 drug:media concentrations versus controls. At 10-fold higher
concentrations (1:100 drug:media), brinzolamide, timolol maleate, and latanoprost showed small increases in LOXL1
expression relative to controls. This effect was not observed with brimonidine tartrate.
Conclusions: These results establish that LOXL1 expression is reduced in lens capsule specimens from XFG individuals
but not XFS. The drug treatment incubation studies suggest that the change in LOXL1 expression observed in XFG is not
attributable to glaucoma drug therapy. If a causative functional relationship can be validated, modification of LOXL1
expression in affected tissues may represent a novel treatment strategy for this disorder.
Pseudoexfoliation  syndrome  (XFS)  is  an  age-related
systemic  disorder  of  the  extracellular  matrix  that  is
characterized  by  abnormal  microfibrillar  production  and
deposition in intra- and extraocular tissues [1]. Structures in
the  anterior  segment  of  the  eye  are  most  often  involved,
including the lens, the iris, the ciliary body, and the zonular
apparatus  [2].  Progressive  pathological  accumulation  of
pseudoexfoliation deposits both from local production and
secondary deposition from the aqueous humor appears to lead
to obstruction of the trabecular meshwork and subsequent
elevation in intraocular pressure [3]. This can lead to optic
nerve  damage  and  the  development  of  pseudoexfoliation
glaucoma  (XFG)  which  is  the  most  common  identifiable
cause of secondary open-angle glaucoma in the world [4].
Compared to primary open-angle glaucoma (POAG), patients
with  XFG  demonstrate  more  rapid  pressure  increase,
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resistance to medical therapy, and more need for glaucoma
surgery [5].
Disease prevalence is estimated at 10% to 20% of the
general population over the age of 60 years [6], and increases
to 40% in individuals 80 years and older [7]. XFS is observed
worldwide with some evidence of geographical clustering.
High prevalence rates have been reported in the Navajo Indian
population (38%) [8], followed by Scandinavia (i.e., Iceland
and  Finland)  at  approximately  20%–25%  [9].  In  northern
Sweden, Astrom et al. [10] concluded that XFS affects every
fourth individual approaching 66 years of age. In contrast, the
Framingham Eye Study from the United States established a
step-wise,  age-correlated  incidence  in  non-glaucoma
individuals that increases from a much lower 0.6% at 52–64
years of age to 5.0% at 75–85 years of age [11]. By far, the
lowest incidence of XFS is found in Eskimo populations in
which it is almost non-existent [9].
In a recent genomic association study, Thorleifsson et al.
[12] identified three single nucleotide polymorphisms (SNPs)
of the lysyl oxidase-like 1 (LOXL1) gene as important genetic
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2236susceptibility  factors  for  XFS  and  XFG  in  Icelandic  and
Swedish  populations.  Subsequent  replication  studies
performed in the United States [13-17], Australia [18], and
Europe [19], have confirmed that two nonsynonymous coding
SNPs  (rs3825942  and  rs1048661)  and  one  intronic  SNP
(rs2165241) from LOXL1 are genetic susceptibility factors for
XFS and XFG. In Indian [20], Japanese [21-26], and Chinese
[27,28]  cohorts,  the  association  with  rs3825942  was  also
replicated and confirmed that this is the strongest risk allele
across different ethnicities. However, the causative nature of
these SNPs is unclear since other studies have shown inverse
relationships for the reported risk alleles of rs3825942 (G),
rs1048661 (G), and rs2165241 (T). The rs3825942 has an
inverse relationship among individuals from South Africa
[29] while rs1048661 and rs2165241 are inversely related
among Japanese [21-26] and Chinese [28] cohorts. Therefore,
the  functional  significance  of  the  LOXL1  gene  in  the
pathogenesis of XFS and XFG is unclear at present.
LOXL1 is located on chromosome 15q24.1 and is part of
a  family  of  five  lysyl  oxidase  enzymes  (LOX,  LOXL1,
LOXL2, LOXL3, and LOXL4) that collectively play a key
role  in  cross-linking  between  collagen  and  elastin  in
connective  tissues  [30].  Individually,  LOXL1  catalyzes
tropoelastin  cross-linking  and  regulates  elastin  fiber
formation and remodeling [31]. Moreover, a growing body of
molecular and biochemical evidence indicates that XFS arises
from a stress-induced elastic microfibrillopathy. Although the
exact pathogenesis of XFS remains unknown, it is believed to
involve inadequate breakdown and/or excessive production of
elastic fiber components [32,33]. Preliminary studies from
cadaveric pseudoexfoliation ocular tissues reveal a reduction
of  LOXL1  gene  expression  in  both  advanced  XFS  (20%
reduction) and XFG (40% reduction) but not early XFS [34].
Furthermore, LOXL1 was identified as a major component of
the abnormal fibrillar material accumulated in XFS and XFG.
Based  on  these  findings,  we  choose  to  study  LOXL1
expression patterns in XFS and XFG using freshly collected
lens capsules from XFS, XFG, and normal control individuals
undergoing cataract surgery. We also studied the effect of four
glaucoma drug medications on LOXL1 expression in primary
human  lens  epithelial  cell  cultures  to  see  if  they  affect
LOXL1 expression.
METHODS
Lens capsule collection: Duke University IRB approval was
obtained before starting the study and informed consent was
obtained from all participating individuals. All patients were
examined by board certified glaucoma or cornea specialists.
Lens capsules were collected at the time of cataract surgery,
immediately stored in RNAlater® (Ambion Inc., Austin, TX),
and subsequently stored at −80 °C until analysis. Controls
were matched to age, sex, ethnicity, and type of cataract.
Pseudoexfoliation  changes  were  identified  as  the
presence of a central disk of XFS material, a clear annular
zone (partial or complete), or flakes of XFS material on the
lens surface, iris, or corneal endothelium in either eye. Patients
were excluded if there was a history of exposure to intense
infrared  light  e.g.,  glassblowing  is  associated  with  true
exfoliation of the lens capsule rather than XFS. XFG was
diagnosed  when  patients  possessed  the  above  XFS
characteristics and at least two of the following criteria: A)
documented intraocular pressure (IOP) ≥22 mmHg in either
eye; B) glaucomatous optic nerve cupping defined as a cup to
disc ratio >0.7 in either eye, notching of the neuroretinal rim,
or  an  asymmetric  cup  to  disc  ratio  >0.2;  and/or  C)
glaucomatous visual field loss consistent with the optic nerve
appearance.  Glaucoma  suspects  were  excluded  from  this
study. Controls were individuals of similar age as the patients
without  any  evidence  of  glaucoma  or  pseudoexfoliation
deposits on intraocular tissues. Their IOPs were in the normal
range (<21 mmHg) with normal-appearing optic nerves.
Cell cultures and medication treatment: Post-mortem human
eyes were obtained within 2 days post-mortem according to
the tenants of the Declaration of Helsinki. Eyes were obtained
from a 42-year-old Caucasian male, a 50-year-old Asian male,
and a 50-year-old Hispanic female. Briefly, extracted lens
capsules (free of any adherent tissues) were cut into small
pieces and digested in medium 199 containing 1.5 mg/ml
collagenase IV and 0.2 mg/ml porcine albumin at 37 °C for
60  min.  At  the  end  of  the  digestion,  the  contents  were
centrifuged 100× g for 10 min at 22 °C, and the cell pellet was
suspended in Dulbecco's modified Eagle medium (DMEM)
containing 20% fetal bovine serum (FBS), penicillin (100
Units/ml), streptomycin (100 μg/ml), and gentamicin (20 μg/
ml), then plated on plastic Petri plates coated with 2% gelatin.
Cell cultures were grown at 37 °C, and under 5% C02. Second
to  fourth  passages  were  used  throughout  this  study.  All
reagents  were  obtained  from  Invitrogen  Corporation
(Carlsbad, CA).
Cell cultures were grown to confluence in four separate
six-well plates (Costar 3516; Costar, Cambridge, MA). Each
plate was then treated with one of four different glaucoma
drugs  once  daily  for  seven  days  (at  1:1,000  or  1:100
concentrations relative to media) with simultaneous change
of media. The 1:1,000 concentration was chosen based on the
relative  bioavailability  of  topical  medications  given  the
barriers to ocular drug permeation such as the precorneal tear
film, corneal epithelial barrier, dilution in the aqueous humor,
and preferential flow toward the trabecular meshwork (and
hence away from the lens) [35]. Since ocular bioavailability
is highly variable, a second 1:100 concentration was studied
to represent a 10-fold increase in drug concentration. These
drugs  were  chosen  because  they  were  used  by  the  XFG
individuals studied and they represent four separate classes of
glaucoma  medications  with  distinct  pharmacology.  They
included:  brinzolamide  1%,  brimonidine  tartrate  0.1%,
timolol maleate 0.5%, and latanoprost 0.005%. Controls were
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manner. After one week of treatment, cells were harvested.
RNA isolation and quantification: Total RNA was isolated
from individual lens capsule samples using an RNeasy kit
(Qiagen Inc., Valencia, CA) according to the manufacturer’s
instructions and then treated with DNase. RNA yields were
measured  using  RiboGreen  fluorescent  dye  (Molecular
Probes, Eugene, OR).
Real-Time PCR: First strand cDNA was synthesized from
0.5 μg of total RNA by reverse transcription using oligodT
and  Superscript  II  reverse  transcriptase  (Invitrogen
Corporation, Carlsbad, CA) according to the manufacturer’s
instructions.  Quantitative  polymerase  chain  reactions  (Q-
PCR) were performed in a 20 µl mixture that contained 1 µl
of the cDNA preparation and 1× iQ SYBR Green Supermix
(Bio-Rad, Hercules, CA), 3 mM MgCl2, and 1 mM of primer.
PCR parameters were as follows: 95 °C for 5 min followed by
50 cycles of 95 °C for 15 s, 65 °C for 15 s, and 72 °C for 15
s. The fluorescence threshold value (Ct) was calculated using
the  iCycle  system  software  (Bio-Rad).  The  absence  of
nonspecific products was confirmed by analysis of the melt
curves.  Primers  flanking  the  sixth  exon  of  LOXL1  were
selected  and  optimized.  β-Actin  (ACTB)  was  used  as  an
internal standard of mRNA expression and to normalize gene
expression levels. The primers and conditions used for Q-PCR
amplification are shown in Table 1.
RESULTS
Lens  capsule  collection:  All  participants  underwent
uncomplicated  clear-corneal  phacoemulsification  cataract
surgery for nuclear sclerotic cataracts. A total of 28 samples
were analyzed: seven XFS, seven XFG, ten cataract control
specimens, and four for quality-control. Individual specimen
yields were too low to perform both quality analysis and Q-
PCR;  therefore,  4  representative  samples  were  randomly
selected for the quality-control analysis. The ages for each
group were not statistically significantly different and the
averages were as follows: XFS (76.3), XFG (73.5), control
(76.5), and quality-control (73.4). Each capsule specimen was
approximately  5  mm  in  diameter.  RNA  yields  were
determined using the Ribogreen fluorescent dye (Molecular
Probes Inc., Eugene, OR) and RNA quality was confirmed
using the Agilent 2100 Bioanalyzer (Agilent Technologies
Inc., Santa Clara, CA).
Expression of LOXL1 in lens capsule specimens: A total of 24
samples  were  analyzed:  seven  XFS,  seven  XFG,  and  ten
cataract control specimens. LOXL1 mRNA expression was
detected in all lens capsule specimens analyzed from the three
different groups (Figure 1). Gene expression was measured
and normalized to control tissue expression. Expression levels
were  similar  in  control  and  XFS  lens  tissue,  whereas
decreased expression was measured in XFG specimens (53%
of control levels [p<0.02]). P-values using Student’s t-tests
demonstrated significant differences between both the control
and XFG and XFS and XFG groups. No significant difference
was observed between the control and XFS group.
LOXL1  expression  in  treated  hLEC:  Real-time  semi-
quantitative  PCR  revealed  no  significant  difference  in
LOXL1 expression between the control groups and the 1:1,000
drug:media  groups  incubated  with  brinzolamide,
brimonidine, timolol maleate, or latanoprost (see Figure 2).
At  10-fold  higher  concentrations  (1:100  drug:media),
brinzolamide,  timolol  maleate,  and  latanoprost  actually
showed increases in LOXL1 expression relative to controls.
This  high-concentration  latanoprost  treatment  (1:100)
demonstrated  the  most  pronounced  increase  in  gene
expression, which was 41% higher (p<0.003) than the control
group. High-concentration brinzolamide and timolol maleate
showed increases of 19% (p<0.05) and 26% (p<0.03) above
normal, respectively. P-values were obtained using two-tailed
t-tests of two-samples with unequal variance. No significant
increase in expression was seen with brimonidine tartrate with
both 1:100 and 1:1,000 concentrations. Thus, drug treatment
results in little change in LOXL1 expression at physiologic
drug concentrations (1:1,000) and increased expression at 10-
fold higher concentrations. This suggests that the decreased
expression levels seen in XFG are not due to drug therapy.
DISCUSSION
LOXL1 has been shown to be strongly associated with XFS
and XFG in every population cohort studied to date. However,
the functional significance of the disease associated SNPs is
unclear since some cohorts have shown inverse relationships
between the initially reported risk alleles. The aim of this study
TABLE 1. PRIMERS USED FOR Q-PCR AMPLIFICATION OF A 220 BP FRAGMENT OF LOXL1 (ACCESSION NUMBER: NM_005576.2).
Gene Sequence Primer E value
LOXL1 F 5′-AGCGCTATGCATGCACCTCTCATA-3′ E: 10−4
LOXL1 R 5′-TGCAGAAACGTAGCGACCTGTGTA-3′ E: 10−4
ACTB F 5′-CCTCGCCTTTGCCGATCCG-3′  
ACTB R 5′-GCCGGAGCCGTTGTCGACG-3′  
        ACTB (accession number: NM_001101.3) control sequences are also as listed. F=forward primer and R=reverse primer.
        E=Primer expected value.
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normal,  XFS,  and  XFG  tissues.  We  choose  lens  capsule
specimens for two reasons: 1) this tissue is a major site of
production of XFS particles and 2) these specimens are easily
obtained at the time of surgery and essentially generate in vivo
expression data. Our results demonstrate that LOXL1 gene
expression is reduced in lens capsule specimens from XFG
but not XFS individuals. The cell culture experiments suggest
that this decrease in expression is not due to a medication
effect since drug incubation does not lead to a decrease in
LOXL1 expression. Even when the drug concentration was
increased ten fold, some of the medications (brinzolamide,
timolol, and latanoprost) resulted in an increase (rather than
decrease) in LOXL1 expression. This observation establishes
that IOP-lowering medications are unlikely to contribute to
the pathological decrease in LOXL1 expression seen in XFG.
Moreover, LOXL1 expression has been suggested to decrease
with  age  [36]  but  in  our  samples,  the  ages  were  similar
between the three groups with the XFG group having the
lowest average age. Therefore, neither age nor medication use
explains the differences we observed.
Our results are similar to those reported by Schlotzer-
Schrehardt et al. [34] in cadaveric ciliary body specimens in
that decreased expression was identified in XFG specimens.
They also reported slightly increased expression in early XFS
and decreased expression in late XFS. However, we do not
have a standard method of distinguishing early versus late
XFS  and  therefore  we  choose  to  analyze  all  the  XFS
individuals together. Furthermore, we did not genotype our
specimens because surgically obtained lens capsules yield
very small quantities of mRNA and DNA which limit the
analyses that could be performed. However, prior published
studies  (including  that  from  our  patient  population)
demonstrate  a  high  prevalence  of  rs3825942  (94%)  and
Figure  1.  Tabulated  LOXL1  gene
expression  in  lens  capsule  specimens
expressed as a percentage of measured
expression  in  normal  specimens.
NOR=normal  cataract,
XFS=pseudoexfoliation  syndrome,
XFG=pseudoexfoliation glaucoma, and
*  denotes  a  p-value  of  <0.02.  A
significant difference in expression was
observed between the NOR and XFG
and  XFS  and  XFG  comparisons.  No
significant difference was seen between
NOR and XFS.
Figure  2.  LOXL1  gene  expression  in
drug-treated (1:1,000 and 1:100) hLEC
using  real-time  PCR.  Data  were
normalized to β-actin (ACTB). Values
represent percent of normal expression
in  controls  ±SEM  of  three  separate
experiments. No significant decrease in
expression was observed in any of the
samples.  Significant  increases  in
expression  were  seen  in  the
Brinzolamide 1:100, Timolol 1:100, and
Latanoprost 1:100 groups. * denotes a
p-value <0.003, ** denotes a p-value
<0.03, and *** denotes a p-value <0.05.
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the  majority  of  our  specimens  likely  contain  the  disease
associated SNPs.
Furthermore, LOXL1 polymorphisms generally have an
equal  prevalence  between  both  XFS  and  XFG  cohorts.
However, in our study, we found decreased expression only
among the XFG group and relatively similar expression levels
between cataract controls and XFS individuals. The reason for
the difference between XFS and XFG is unclear at present and
suggests  that  there  may  be  other  modifying  genetic  or
environmental  factors  that  play  a  role  in  glaucoma
development.
The results of this study suggest a causative functional
relationship  between  LOXL1  expression  and
pseudoexfoliation  glaucoma.  We  surmise  that  decreased
LOXL1  expression  promotes  the  accumulation  of
pseudoexfoliation particles that appear on histology to clog
the trabecular meshwork, collapse Schlemm’s Canal, and lead
to  increased  IOP  as  seen  in  XFG  [3,37].  If  a  causative
functional  relationship  can  be  validated,  modification  of
LOXL1 expression in affected tissues may represent a novel
treatment strategy for this disorder.
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